GICS Sector : Healthcare
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients.Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company
Nov -29
Campbell & CO Investment Adviser LLC Acquires New Position in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA
Nov -18
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying
Nov -17
Why Centessa Pharmaceuticals Stock Crushed the Market Today
Nov -12
Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares
Nov -12
Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
Nov -11
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov -07
46,665 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Purchased by Y Intercept Hong Kong Ltd
Nov -06
Centessa Pharmaceuticals plc's 9.27% growth is driven by increasing demand for rare disease treatments, strategic partnerships, and a strong pipeline of novel therapies. The company's focus on gene therapy and small molecule development also contributes to its growth, as well as its ability to leverage its platform to identify and acquire promising assets.
CX-102 is a novel, oral, small molecule inhibitor of serine/threonine kinase 1 (STK11) for the treatment of solid tumors.
CX-202 is a novel, oral, small molecule inhibitor of cyclin-dependent kinase 2/4/6 (CDK2/4/6) for the treatment of breast cancer and other solid tumors.
CX-205 is a novel, oral, small molecule inhibitor of fibroblast growth factor receptor 1-3 (FGFR1-3) for the treatment of solid tumors.
CX-611 is a novel, oral, small molecule inhibitor of bromodomain and extra-terminal motif (BET) for the treatment of hematological malignancies.
Centessa Pharmaceuticals plc has a moderate threat of substitutes due to the availability of alternative treatments and therapies for the diseases it targets.
Centessa Pharmaceuticals plc has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative options for patients.
Centessa Pharmaceuticals plc has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and the company's dependence on a few key suppliers.
Centessa Pharmaceuticals plc has a high threat of new entrants due to the growing demand for pharmaceuticals and the increasing number of biotech startups entering the market.
Centessa Pharmaceuticals plc operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 24.27% |
| Debt Cost | 11.19% |
| Equity Weight | 75.73% |
| Equity Cost | 11.19% |
| WACC | 11.19% |
| Leverage | 32.04% |
Value: 8.4
Growth: 6.8
Quality: 5.2
Yield: 0.0
Momentum: 10.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.0
Growth: 3.9
Quality: 4.7
Yield: 0.0
Momentum: 8.0
Volatility: 0.7
1-Year Total Return ->
Value: 6.2
Growth: 4.0
Quality: 4.3
Yield: 0.0
Momentum: 4.5
Volatility: 0.3
1-Year Total Return ->
Value: 6.0
Growth: 4.2
Quality: 3.8
Yield: 0.0
Momentum: 4.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.0
Growth: 3.7
Quality: 1.9
Yield: 0.0
Momentum: 1.0
Volatility: 3.3
1-Year Total Return ->
Value: 6.0
Growth: 2.2
Quality: 3.4
Yield: 0.0
Momentum: 0.0
Volatility: 1.3
1-Year Total Return ->